Holosight

  • Research type

    Research Study

  • Full title

    Long-term safety after Holoclar® implant for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns: observational study of routine clinical practice.

  • IRAS ID

    184635

  • Contact name

    Francisco Figueiredo

  • Contact email

    francisco.figueiredo@ncl.ac.uk

  • Sponsor organisation

    Holostem S.r.l.

  • Clinicaltrials.gov Identifier

    ., ENCePP

  • Duration of Study in the UK

    6 years, 2 months, 0 days

  • Research summary

    Holosight is an observational, non-interventional trial with the primary objective of expanding the body of data so far collected and evaluating the long-term safety profile of patients treated with Holoclar® during a 5-year follow-up period, through the description of the occurrence of adverse events, adverse drug reactions, serious adverse events and adverse events of special interest. Holoclar® is an authorized new treatment indicated for treatment of patients with moderate to severe limbal stem cell deficiency (LSCD) resulting from physical or chemical ocular burns. The treatment of Holoclar® and the associated postsurgical treatment/ assessments will be performed under routine clinical conditions and do not form part of this trial.
    The registry will include the first 100 patients treated in the routine clinical practice setting who agree to participate in the registry. Eligible patients receiving Holoclar® will be consecutively included with the first observation being made at the time of corneal biopsy and will be followed for 5 years after the first implant. Follow-up visits are foreseen, according to clinical practice and clinical judgment. Data on the variables collected as part of this routine clinical care will be retrieved from the medical charts available at the centers and Clinical Investigators enrolling patients in this study will record data on the electronic case report forms, which will capture and check the data foreseen in this protocol. Further Patient QoL will be measured by means of EQ-5D and NEI VFQ-25.

  • REC name

    North of Scotland Research Ethics Committee 2

  • REC reference

    17/NS/0113

  • Date of REC Opinion

    12 Dec 2017

  • REC opinion

    Further Information Favourable Opinion